Aug 13, 2024
For most of the last century, breast cancer was categorized only by its location in the body; as a result, treatment results varied significantly. Patients with metastatic HER2+ breast cancer were traditionally treated with conventional chemotherapy regimens until trastuzumab became available. In September 1998, th...
Read More...
Aug 13, 2024
Every year during Breast Cancer Awareness Month, numerous campaigns aim to raise awareness about breast cancer, its symptoms, early diagnosis, and treatment options. Significant progress has been made in managing breast cancer, assessing its risks, and treating it through a combination of surgery, radiation, and ot...
Read More...
Aug 08, 2024
Breast cancer is a serious and most common problem in developed as well as developing countries. According to the World Health Organization (WHO), more than 2.3 million cases of breast cancer occur each year, making it the most common cancer among adults. In 95% of countries, breast cancer is either the leading ...
Read More...
Aug 08, 2024
HR+/HER2- Breast Cancer is the most prevalent form of breast cancer. This type accounts for a higher percentage among all breast cancers. Hormone receptors are proteins that receive hormone signals and cue the cancer cells to grow. If breast cancer cells get signals from the hormone estrogen that could promote tumo...
Read More...
Aug 08, 2024
More than a dozen companies have shifted their focus toward the development of HR-positive/HER2-negative breast cancer drugs. Some of them are Regor Therapeutics, Seagen Inc., CytomX Therapeutics, Taizhou EOC Pharma, Chia Tai Tianqing Pharmaceutical Group, AstraZeneca, Daiichi Sankyo, Inc., Tyme, Inc., Seagen Inc.,...
Read More...
Aug 08, 2024
Breast cancer is a complex disease that occurs when abnormal cancerous cells in the breast grow uncontrollably, forming tumors. This condition typically originates in the ducts or lobules of the breast. Various signals, including hormonal signals, often influence the growth of cancer cells. Understanding the specif...
Read More...
Aug 08, 2024
Breast cancer is not a single disease leading to abnormal cell division in breast tissues. Breast cancer is the most common form of cancer in women. Each year, it affects over 2 million women globally and is the most significant cause of death among women. According to DelveInsight’s estimates, there were aro...
Read More...
Apr 02, 2024
Voydeya Receives FDA Approval as Supplemental Treatment with Ravulizumab or Eculizumab for Managing Extravascular Hemolysis in Adult Patients with PNH Voydeya (danicopan) has received approval in the United States for use alongside ravulizumab or eculizumab in treating extravascular hemolysis (EVH) in adults dia...
Read More...
Mar 05, 2024
Acoramidis Joins Bayer's Robust Lineup, Boosting Cardiology Solutions Bayer has obtained the exclusive rights to market acoramidis in Europe from Eidos Therapeutics Inc., BridgeBio International GmbH, and BridgeBio Europe B.V. Acoramidis, a highly potent and selective small molecule given orally, functions as a ...
Read More...
Jan 16, 2024
Bayer’s AskBio initiates Phase II GenePHIT trial in Congestive Heart Failure Merck, also recognized as MSD in regions beyond the United States and Canada, has officially announced that the FDA has approved for the use of KEYTRUDA, Merck's anti-PD-1 therapy, in conjunction with chemoradiotherapy (CRT) for treatin...
Read More...
Understanding Bone Densitometers: Technology, Applications, and Impact on Bone Health
Nov 04, 2025
Wireless Brain Sensors: Revolutionizing Neuroscience and Healthcare
Oct 28, 2025
Discover How Learning Disability Treatment Landscape is Evolving with the Emergence of Digital Assistant Technologies
Jul 04, 2025
A New Era for Multiple Myeloma Treatment: Bispecific Antibodies Enter the Fray
Jun 10, 2025
Newsletter/Whitepaper